SEATTLE, June 03, 2021, (MEDGADGET) — Overview:
GM1 gangliosidosis is an inherited disorder that progressively destroys nerve cells in the brain and spinal cord. This condition is classified into three major types; Type 1 includes severe signs and symptoms, Type 2 usually occurs in newborns and exhibit symptoms such as mental regression till the age of 18. While type 3 usually occurs in adults and exhibit a very low disease spectrum.
In January 2020, the World Health Organization (WHO) declared that the outbreak constitutes a Public Health Emergency of International Concern (PHEIC), following the recommendations of the Emergency Committee.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/4270
The pandemic has adversely affected the global GM1 gangliosidosis treatment market. The pandemic has also hampered the demand, production, and supply of raw materials, disrupting distribution channels. Moreover, due to irregularities in transportation, many countries such as Egypt, UAE, Saudi Arabia, India, China, and others are facing problems regarding the transport of drugs.
Increasing incidence of GM1 gangliosidosis is expected to drive the global GM1 gangliosidosis treatment market growth during the forecasted period. According to World Health Organization (WHO), worldwide, about 2,000 people suffer from GM1 ganglioside in 2019. Moreover, GM1 gangliosidosis accounts for around 0.5-1.0/100,000 births worldwide.
Moreover, increase in research and development for the development of GM1 gangliosidosis treatment is expected to propel growth of the global GM1 gangliosidosis treatment market.
Lack of awareness among people about GM1 gangliosidosis is expected to hamper the global GM1 gangliosidosis treatment market growth.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/4270
By Product Type:
By Disease Type:
- Type 3 GM1 Gangliosidosis
- Type 1 GM1 Gangliosidosis
- Type 2 GM1 Gangliosidosis
- North America
- Rest of World
North American is expected to witness substantial growth in the global GM1 Gangliosidosis Treatment market due to high disease population in the region, especially in the United States. According to the National Center for Biotechnology Information (NCBI), in 2019, the GM1 gangliosidosis accounted for about 500 patients in the U.S.
Key players active in the global GM1 Gangliosidosis Treatment market are Passage Bio and Lysogene and Axovant Gene Therapies Ltd.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/gm1-gangliosidosis-treatment-market-3533
In May 2017, Lysogene and Brammer Bio signed a strategic agreement to help Brammer Bio manufacture LYS-GM101, an AAVrh10-based gene therapy to treat GM1 gangliosidosis.
Other Related Reports:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027